Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

Enfortumab Vedotin [Padcev®]

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Subsidy Information and Financing Scheme

Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List

Active ingredient: Enfortumab Vedotin

General information

Subsidy Information and Financing Scheme

[MSHL] Enfortumab vedotin Powder For Concentrate For Solution For Infusion 20 mg, 30 mg

  1. Treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

View legend

Drug Guidance for Subsidy

01/07/2026 Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer (opens in new tab)

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Enfortumab vedotin 20 mg and 30 mg powder for concentrate for solution for infusion, in combination with pembrolizumab, for untreated locally advanced or metastatic urothelial cancer.

Funding status

[R] Enfortumab vedotin 20 mg and 30 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

[NR] MAF assistance does not apply to pembrolizumab for this indication.

Clinical indication, subsidy class and MediShield Life claims eligibility for enfortumab vedotin are provided in the Annex.

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Padcev® Powder For Concentrate For Solution For Infusion 20 mg

  1. National Cancer Centre

  2. National University Hospital

Padcev® Powder For Concentrate For Solution For Infusion 30 mg

  1. National Cancer Centre

  2. National University Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab).

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information.

Intravenous

* Clinical information is available for this product.